SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The SolyCat is a symbol of energy and mystery. Shining like the sun and agile as a feline.  Solycat is here to take over Solana! Inspired by Shiba Inu’s legendary rise on Ethereum, Solycat is the ultimate meme coin designed for Solana’s fast and scalable blockchain.  Our mission is simple: become the top cat of Solana. With bold branding, a vibrant community, and unstoppable momentum, Solycat is ready to dominate. This isn’t just another token—it’s a movement powered by fun, creativity, and the spirit of decentralization.  Join the pride and let’s make history, one paw at a time!

Solycat

Solycat is gaining attention, with community members highlighting its recent launch on Phantom Wallet and potential for significant growth. The conversation revolves around 'moon' and 'rocket' references suggesting possible rapid price appreciation. Some users are pointing out potential scam risks.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is trending as investors closely monitor the Gen AI Summit for potential catalysts, with speculation around new contracts and strategic partnerships driving community interest; analysts have increased price targets, further fueling the bullish sentiment. Discussions also focus on the company's competitive positioning in the AI data market and its potential for expansion into enterprise and government sectors. Despite some concerns about high valuation, the overall tone remains optimistic, as investors eagerly await further developments and Q3 earnings results.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals is trending due to upcoming FDA decision on Revuforj for relapsed/refractory AML, with the community actively debating the potential impact of approval and existing safety warnings. Discussions revolve around the drug's market potential, comparison to competitors like Kura, and speculation about a possible buyout. Investors are weighing potential gains against concerns about short positions and market manipulation.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

Grayscale Bitcoin Mini Trust ETF is trending amid discussions about Bitcoin's recent price movements, particularly its approach to all-time highs and potential for further gains. Community members are weighing in on factors like institutional investment, regulatory developments, and the impact of potential government shutdowns, while also debating whether Bitcoin is a safe haven asset or a speculative investment. There is active speculation on short squeezes, market manipulation, and potential rotation into other assets like gold.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as the community discusses its potential, recent news around Ripple, and possible utility. Some are focused on the potential impact of XRP ETFs, while others highlight Ripple's partnerships and real-world use cases. Community members are also discussing XRP's price action and potential decoupling from Bitcoin.

Jump into the crypto fun with $SOLCAT! Our token features a savvy cat wearing a fabulous Solana hat, offering super cool adventures in the world of meme coins.

CatSolHat

CatSolHat ($SOLCAT) is trending as the community promotes its launch and availability on Phantom Wallet. Social media conversations highlight its branding as 'Solana's sleekest predator' and encourage buying. The coin is being discussed alongside other Solana-based tokens and major cryptocurrencies like Bitcoin.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

Recursion Pharmaceuticals Inc - Ordinary Shares - Class A

Recursion Pharmaceuticals Inc

RXRX is trending due to increased interest in AI-driven healthcare solutions, particularly after presenting at the GITEX Global conference in Dubai. The community is focused on the stock's high short interest and potential for a short squeeze, referencing NVIDIA's investment as a positive signal. Some anticipate news or catalysts that could trigger a significant upward move.

Baby Doge Coin is a meme cryptocurrency designed to be deflationary and more scarce over time. All holders of Baby Doge will earn more baby doge that is automatically sent to your wallet by simply holding Baby Doge coins in your wallet. Watch the amount of baby doge grow in your wallet as baby doge coin holders automatically receive a 5% fee from every on chain transaction that happens on the Baby Doge ecosystem. The community receives more baby doge coins from the fees generated each transaction.

Baby Doge Coin

Baby Doge Coin is trending as the community anticipates potential listings on major exchanges like Coinbase and Crypto.com, speculating about a possible surge. Discussions also revolve around its relationship with Dogecoin and potential for significant gains in the coming years, with some comparing its current trajectory to Shiba Inu's earlier days.

Aflac, Inc. is a holding company, which engages in the provision of financial protection services. It operates through the following segments: Aflac Japan and Aflac U.S. The Aflac Japan segment offers life insurance, death benefits, and cash surrender values. The Aflac U.S. segment sells voluntary supplemental insurance products for people who already have major medical or primary insurance coverage. The company was founded by John Amos, Paul Amos and William Amos on November 17, 1955 and is headquartered in Columbus, GA.

Aflac Inc.

Aflac is trending as traders discuss potential options strategies and ROI opportunities, with particular interest in calls expiring in 2025 and 2027. Community members are weighing the stock's technical indicators, buyback program, and analyst ratings, while considering both short-term gains and long-term dividend prospects. Some investors are reacting to recent news, including updated ratings from analysts and the company's cybersecurity incident disclosure.

AABG Token

AABB is trending as investors discuss the potential for a share squeeze and look forward to upcoming news regarding the wallet, dividends, and a potential legal action against market manipulation. Community members express confidence in the company's progress and are accumulating shares while awaiting key catalysts. The rise in gold and silver prices is also fueling optimism for AABB's future.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biotech stocks remain a hot sector for retail traders on Stocktwits,&nbsp;which collectively boast over 3.45 million followers.&nbsp;In January, several biotech names saw explosive gains as investors bet on breakthrough treatments, key partnerships, and regulatory milestones.According to Stocktwits data, these five biotech stocks saw the highest surge in retail following this month.CARGO Therapeutics Inc. (CRGX) – 445% Jump In FollowersCARGO Therapeutics, a clinical-stage biotech company focused on cancer treatments, saw its stock collapse even as retail interest surged.&nbsp;In January, the FDA cleared its Investigational New Drug (IND) application for CRG-023, a novel tri-specific CAR T therapy designed to tackle relapse factors in B-cell malignancies.&nbsp;However, the company later announced it would discontinue a Phase II trial of its lead candidate, firi-cel, after an ad hoc safety analysis revealed an unfavorable benefit-risk profile.&nbsp;Wall Street analysts issued downgrades, and CARGO’s stock is on track to plunge more than 76% in January — its worst month since going public in November 2023.&nbsp;Short interest stands at 15.1%, according to Koyfin data.Sana Biotechnology Inc. (SANA) – 185% Jump In FollowersSana Biotechnology, which focuses on engineered cell therapies, captured investor attention with a potential&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sana-biotech-stock-triples-after-type-1-diabetes-trial-data/chGBWsVRZO">breakthrough</a> in type 1 diabetes.&nbsp;The company demonstrated earlier this month that its hypoimmune edits allowed islet cell transplant survival without immunosuppression.&nbsp;Analysts praised the findings, driving the stock up roughly 114% in January — its best month since its March 2021 market debut.&nbsp;Short interest is at 16.6%.Silexion Therapeutics Corp. (SLXN) – 92% Jump In FollowersSilexion, an oncology-focused biotech developing RNA interference therapies, gained momentum after releasing preclinical data on a second-generation siRNA candidate, SIL-204.&nbsp;The treatment&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/slxn-stock-hits-record-low-after-pricing-5m-offering/chGtwKoRng">showed</a> synergistic efficacy when combined with first-line chemotherapy for pancreatic cancer.&nbsp;Although the stock gained just 2% in January, it marked its best month since November.&nbsp;Short interest remains low at 2.4%.AEON Biopharma Inc. (AEON) – 81% Jump In FollowersAEON Biopharma is developing ABP-450, a botulinum toxin complex similar to Evolus’ Jeuveau, for medical indications such as chronic migraine.&nbsp;Retail traders appeared to buy the dip after AEON priced a $20 million public offering earlier this month, which initially sent shares tumbling.&nbsp;The stock is headed for a 77% drop in January, its worst month since going public via a SPAC merger in July 2023.&nbsp;Short interest is just 0.2%, according to Koyfin.Kairos Pharma (KAPA) – 78% Jump In FollowersKairos Pharma, a clinical-stage biopharmaceutical company, saw retail interest soar this month after breaking key resistance levels and securing crucial investments.&nbsp;The company is testing its lead candidate, ENV105 — which targets a protein linked to resistance in cancer treatments — in Phase 2 trials for castrate-resistant prostate cancer and Phase 1 trials for lung cancer.The stock gained momentum following CEO John Yu’s positive comments at an investor healthcare summit this month and the completion of a $3.5 million PIPE transaction.&nbsp;Kairos shares are set to decline 2.6% in January, marking their worst month since October.&nbsp;Short interest remains&nbsp;negligible at 0.1%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

Retail Traders Flocked To These 5 Biotech Stocks In January — Here’s Why

Biotech remains a high-risk, high-reward sector, and this month’s top draws reflect retail’s appetite for stocks with major clinical and regulatory catalysts.

Equity

Biotech remains a high-risk, high-reward sector, and this month’s top draws reflect retail’s appetite for stocks with major clinical and regulatory catalysts.


The biotech sector remains a hotbed for retail investor interest, with over 3.4 million users following these stocks on Stocktwits. Last week, the below three companies saw the highest increases in retail following:Kairos Pharma Ltd. (+83%)Kairos Pharma, a clinical-stage biopharmaceutical company focused on cancer therapeutics, saw the most spike in retail chatter.&nbsp;The company is testing its lead candidate, ENV105 — which targets a protein linked to resistance in cancer treatments — in Phase 2 trials for castrate-resistant prostate cancer and Phase 1 trials for lung cancer.Retail interest soared last week after Kairos broke key resistance levels and secured crucial investments.&nbsp;The stock surged nearly 120% last Monday following positive comments from CEO John Yu at an investor healthcare summit.&nbsp;Additionally, the company completed a $3.5 million PIPE transaction, which the CEO said would ensure the continued progress of its clinical trials and asset development.&nbsp;Despite these gains, Kairos has lost 21% of its value since its NYSE debut in September.OS Therapies Inc. (+39%)Shares of OS Therapies jumped after the company reported positive clinical trial data for its OST-HER2 candidate, which targets a rare bone cancer that spreads to the lungs.&nbsp;Following the announcement, Maxim analyst Jason McCarthy raised the firm’s price target to $15 from $8, maintaining a ‘Buy’ rating.&nbsp;The data has positioned OS Therapies to meet with the FDA by the end of the first quarter of 2025 to discuss the possibility of filing for accelerated approval.The company is focused on oncology treatments, with OST-HER2 being its lead immunotherapy asset. It leverages listeria bacteria’s immune-stimulatory effects to target the HER2 protein in cancer cells.AEON Biopharma Inc. (+19%)AEON Biopharma is a company developing the proprietary botulinum toxin complex ABP-450, a biosimilar to Evolus’ Jeuveau, approved for cosmetic use, but AEON is developing it for medical indications.&nbsp;The company’s manufacturing partner, Daewoong, produces ABP-450 in FDA-approved facilities under current Good Manufacturing Practices (cGMP).Although there were no specific catalysts driving the recent spike, it appears that retail investors were buying the dip after the company priced a public offering to raise $20 million earlier this month, which had caused the stock to slide.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Kairos, OS Therapies, AEON See Highest Weekly Spike In Retail Following Among Biotechs: Here's Why

Cancer treatments, FDA breakthroughs, and other developments fueled a sharp spike in interest for these biotech players, as investors bet on promising clinical data and strategic moves.

Cryptocurrencies were on fire last week and therefore it should come as no surprise that Stocktwits users turned their attention increasingly toward the crypto and allied space. Among the 10 stocks that saw the biggest increase in watcher count on Stocktwits, four were cryptocurrencies and two were Bitcoin miners.Here’s a compilation of stocks/cryptos that were closely followed by retail last week along with their watcher count:<ul><li>Dogecoin (<a class="mention" data-mention="$DOGE.X" data-symbol-id="DOGE.X" href="https://stocktwits.com/symbol/DOGE.X" target="_blank">$DOGE.X</a>) (336,178)</li><li>SPDR S&amp;P 500 ETF Trust (<a class="mention" data-mention="$SPY" data-symbol-id="SPY" href="https://stocktwits.com/symbol/SPY" target="_blank">$SPY</a>) (537,941)</li><li>Bitcoin (<a class="mention" data-mention="$BTC.X" data-symbol-id="BTC.X" href="https://stocktwits.com/symbol/BTC.X" target="_blank">$BTC.X</a>) ($601,174)</li><li>Ripple (<a class="mention" data-mention="$XRP.X" data-symbol-id="XRP.X" href="https://stocktwits.com/symbol/XRP.X" target="_blank">$XRP.X</a>) (174,221)</li><li>Innovation Beverage Group Ltd. (<a class="mention" data-mention="$IBG" data-symbol-id="IBG" href="https://stocktwits.com/symbol/IBG" target="_blank">$IBG</a>) (1,260)</li><li>Tesla, Inc. (<a class="mention" data-mention="$TSLA" data-symbol-id="TSLA" href="https://stocktwits.com/symbol/TSLA" target="_blank">$TSLA</a>) (980,127)</li><li>PepeCoin (<a class="mention" data-mention="$PEPE.X" data-symbol-id="PEPE.X" href="https://stocktwits.com/symbol/PEPE.X" target="_blank">$PEPE.X</a>) (17,692)</li><li>Kairos Pharma Ltd. (<a class="mention" data-mention="$KAPA" data-symbol-id="KAPA" href="https://stocktwits.com/symbol/KAPA" target="_blank">$KAPA</a>) (1,076)</li><li>Mara Holdings Ltd. (<a class="mention" data-mention="$MARA" data-symbol-id="MARA" href="https://stocktwits.com/symbol/MARA" target="_blank">$MARA</a>) (147,043)</li><li>BTC Digital Ltd. (<a class="mention" data-mention="$BTCT" data-symbol-id="BTCT" href="https://stocktwits.com/symbol/BTCT" target="_blank">$BTCT</a>) (4,228)</li></ul>Dogecoin:&nbsp;Dogecoin, a meme coin, was on a tear last week as it went past the $0.40 level before pulling back since the mid-week. The retail crowd are factoring in the meme crypto breaking above its May 2021 highs of $0.74.&nbsp;SPY: The SPY, which is an exchange-traded fund that tracks the broader S&amp;P 500 Index, closed at a record high of $598.76 last Monday. The ETF has come under pressure since then amid fears that the Federal Reserve may give rate cuts a pass at the December meeting. As the year draws to the close and the market enters a seasonally strong period, retail interest in the ETF has been on the rise.Bitcoin:&nbsp;Donald Trump’s victory in the Nov. 5 election has set in motion broad-based buying in the crypto space amid hopes his policies would be more crypto-friendly. Bitcoin rose to a record high past the $93K level last week before pulling back to the $90K level. It has started the new week on a firmer note and has rebounded toward the $92K level.Ripple: Blockchain company Ripple’s native coin, the XRP, rallied past the $1 against the U.S. dollar last week amid hopes that SEC Chair Gary Gensler would be replaced. The current SEC Chair has gone after Ripple and the regulator has an ongoing lawsuit against the company for raising&nbsp;more than $1.3 billion in 2013 by selling XRP in an unregistered public offering.&nbsp;Innovation Beverage: Australian beverage maker Innovation Beverage, which sells domestically and in the U.S., saw its Nasdaq-listed shares jump 40% last week. The gains have been accompanied by a surge in volumes traded. Following a recent initial public offering, the stock was listed on Sept. 26.Retailers on the Stocktwits see scope for further upside as some of them pointed to the stock being a subject of interest on WallStreetBets reddit forum.Tesla: Trump’s victory led to a surge in Tesla shares past the $350 mark (on an intraday basis) last week but they have pulled back since then. Tesla investors view Elon Musk’s closeness to Trump as a positive for the stock even as the company’s electric-vehicle business is awaiting an inflection.PepeCoin:&nbsp;PepeCoin, another meme coin that has generated interest among retailers, more than doubled in the seven sessions that ended Nov. 9, coinciding with the presidential election. It topped $5 on Nov. 9 but has retreated since then and traded around the $4 mark.&nbsp;&nbsp;Kairos Pharma: Shares of California-based nano-cap oncology-focused clinical-stage biotech Kairos surged past $2 on Tuesday on above-average volume, with retail frenzy propping up the stock.. The buying continued in the next session before moderating. Kairos is a newly public company and was listed in mid-September.&nbsp;Mara Holdings:&nbsp;Bitcoin miner Mara’s shares plunged on Wednesday after the company reported a third-quarter revenue miss. Retail, however, is betting on the company in the hopes that the Bitcoin rally could help the miner stage a comeback.BTC Digital:&nbsp; BTC Digital shares soared over 950% to $19.27 in the week ended Nov. 15, rising from under $2 in the previous week. Retailers on the Stocktwits are bullish on the bitcoin miner.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/10-stocks-with-biggest-message-volume-on-stocktwits/cJ4HwPIRQP">10 Most Active Stocks On Stockwits Last Week With Message Volume Spurt</a>For updates and corrections email newsroom@stocktwits.com&nbsp;

Trump trades have continued to evince retail attention. 

10 Stocks/Cryptos With Biggest Increases In Followers On Stocktwits Last Week

Dogecoin, SPY, Bitcoin, Ripple and Innovation Beverage were among the securities that drew retail attention last week.

Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of novel and transformative drug therapies to treat cancer. It focuses on the research and development of immunotherapies for oncology. The company was founded by John S. Yu on June 17, 2013 and is headquartered in Los Angeles, CA.

Kairos Pharma Ltd.

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Current Price	N/A
Prev Close	N/A
Open	N/A
Dividend Yield	0.00%
50-Day Moving Average	$1.31
Beta	0.56
Avg. Volume	1.96M
PE Ratio	-3.46

52-Week High	$3.25
52-Week Low	$0.40
Market Capitalization	$22.61M
EPS (Annual)	-$0.1895
Price to Book	3.23
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

KAPA
Kairos Pharma Ltd.

Feed

News

Sentiment

Fundamentals

Info

Latest KAPA News

KAPAKairos Pharma Ltd.